Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 1.00 |
| ▸ | HCRTR1 known ✓ | O43613 | 3/20 | 1.00 |
| ▸ | HCRTR2 known ✓ | O43614 | 2/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.98 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.98 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.98 |
| ▸ | MEN1 | O00255 | 5/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 3/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29440043 | 1.00 | HTR2C (1.00) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL29424927 | 0.99 | MAPT (1.00) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL496853 | 0.99 | MAPT (1.00) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL29424773 | 0.99 | MAPT (1.00) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL5816617 | 0.88 | MEN1 (0.79) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL13916411 | 0.87 | MEN1 (0.79) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| Hydrochloric Acid SCHEMBL7655785 | 0.86 | HTR2C (0.98) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| Hydrochloric Acid SCHEMBL7660393 | 0.80 | HTR2C (0.76) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| Hydrochloric Acid SCHEMBL5964636 | 0.80 | HTR2C (0.76) | HTR2CHCRTR1HCRTR2ADORA2AMAPT | |
| SCHEMBL7098595 | 0.79 | HTR2C (0.77) | HTR2CHCRTR1HCRTR2ADORA2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-08-10 | — | — | US | claimed |
| EP-1075478-B1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | claimed |
| US-6372757-B1 | OREXIN RECEPTORS FOR SLEEP DISORDERS AND EATING DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-16 | — | — | US | claimed |
| US-20210315963-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS, LLC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3833373-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Diapin Therapeutics LLC (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112739365-A | Tripeptides and treatment of metabolic, cardiovascular and inflammatory disorders | 糖平制药公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020033919-A1 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | DIAPIN THERAPEUTICS, LLC (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-20040157922-A1 | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-12 | — | — | US | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| EP-1075478-B1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6372757-B1 | OREXIN RECEPTORS FOR SLEEP DISORDERS AND EATING DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157922-A1 | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments | CPS1, DPP4, ACAA2 | HTR2C 1736/4885HCRTR1 3297/4885HCRTR2 2846/4885 |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | HTR2C 3135/4885HCRTR1 3864/4885HCRTR2 4023/4885 |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | UGP2, UGDH, UGT1A1 | HTR2C 4164/4885HCRTR1 2850/4885HCRTR2 3033/4885 |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | HTR2C 2771/4885HCRTR1 3797/4885HCRTR2 3206/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | HTR2C 2920/4885HCRTR1 3694/4885HCRTR2 3100/4885 |
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | HCRTR2, HCRTR1, GRIN2B | HTR2C 172/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | HTR2C 1526/4885HCRTR1 154/4885HCRTR2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.